Pfizer Inc. (NYSE:PFE) Shares Acquired by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC increased its position in Pfizer Inc. (NYSE:PFE) by 1.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 155,044 shares of the biopharmaceutical company’s stock after purchasing an additional 2,324 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Pfizer were worth $4,113,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Tompkins Financial Corp boosted its holdings in Pfizer by 5.6% in the fourth quarter. Tompkins Financial Corp now owns 42,736 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 2,253 shares during the last quarter. RDA Financial Network raised its position in shares of Pfizer by 497.9% in the 4th quarter. RDA Financial Network now owns 64,994 shares of the biopharmaceutical company’s stock valued at $1,724,000 after purchasing an additional 54,124 shares in the last quarter. KMG Fiduciary Partners LLC boosted its stake in shares of Pfizer by 5.9% during the 4th quarter. KMG Fiduciary Partners LLC now owns 105,809 shares of the biopharmaceutical company’s stock valued at $2,807,000 after buying an additional 5,917 shares during the last quarter. Empirical Asset Management LLC grew its position in shares of Pfizer by 383.4% during the fourth quarter. Empirical Asset Management LLC now owns 49,622 shares of the biopharmaceutical company’s stock worth $1,316,000 after buying an additional 39,356 shares in the last quarter. Finally, Edge Wealth Management LLC increased its stake in shares of Pfizer by 6.2% in the fourth quarter. Edge Wealth Management LLC now owns 8,517 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 500 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PFE shares. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Stock Performance

Shares of PFE opened at $26.30 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a fifty day moving average of $26.09 and a 200-day moving average of $28.00. The company has a market cap of $149.06 billion, a price-to-earnings ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.